Kaleido Biosciences (Kaleido Biosciences) Interest Expense : $-2.84 Mil (TTM As of Dec. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kaleido Biosciences's interest expense for the three months ended in Dec. 2021 was $ -0.72 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2021 was $-2.84 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kaleido Biosciences's Operating Income for the three months ended in Dec. 2021 was $ -19.70 Mil. Kaleido Biosciences's Interest Expense for the three months ended in Dec. 2021 was $ -0.72 Mil. Kaleido Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kaleido Biosciences Interest Expense Historical Data

The historical data trend for Kaleido Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences Interest Expense Chart

Kaleido Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

-0.44

-1.01

-0.98

-2.80

-2.84

Kaleido Biosciences Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Interest Expense	Get a 7-Day Free Trial														-0.72	-0.71	-0.71	-0.71	-0.72

Kaleido Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84 Mil.

Kaleido Biosciences (OTCPK:KLDO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kaleido Biosciences's Interest Expense for the three months ended in Dec. 2021 was $-0.72 Mil. Its Operating Income for the three months ended in Dec. 2021 was $-19.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2021 was $5.55 Mil.

Kaleido Biosciences's Interest Coverage for the quarter that ended in Dec. 2021 is calculated as

Kaleido Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kaleido Biosciences (Kaleido Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Lexington, MA, USA, 02421

Website

http://www.kaleido.com

Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.

Executives

Alison S Long	officer: Chief Medical Officer	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan	officer: Chief Scientific Officer	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella	director, officer: Chief Executive Officer	79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas	director	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke	officer: CHIEF FINANCIAL OFFICER	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo	officer: Principal Accounting Officer	25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer	director	C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn	officer: General Counsel	128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney	director, officer: Executive Chair	65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142